The development of gentle and effective laser therapies in urology has experienced a technological breakthrough in recent years. In the field of medical technology, companies such as biolitec have continuously developed urological laser therapies. Due to the wide spectrum of fibres and the stepless adjustment of the LEONARDO lasers, the individually required tissue effect (e.g.: incision, excision, vaporization, hemostasis and coagulation of soft tissue) on a wide variety of tissue types is possible. Thus, it is possible to work with precision, which can prevent the occurrence of undesirable side effects such as incontinence, impotence or other sexual dysfunctions. With the laser system, it is possible to treat benign prostatic hyperplasia, condylomas, tumours of the bladder, pelvic floor, urethra, and even kidney tumours.
LIFE laser therapy for benign prostatic hyperplasia BPH is a transurethral resection performed via cystoscopy. Due to the excellent hemostasis in haemoglobin and water, the tissue can be ablated with extreme precision. In doing so, the special contact fibres provide an unbeaten ablation rate and ensure smooth surfaces. The formation of retrograde ejaculation can be avoided by sparing the internal sphincter of the urinary bladder.
Advantages of laser therapy
In partial nephrectomy, the treatment area is reached minimally invasively by means of laparoscopy. For this purpose, biolitec supplies state-of-the-art fibres that ensure optimal nephron sparing. Parenchymal damage and ischemia times are reduced to an absolute minimum with this therapy. In addition, the blood supply to the kidney does not have to be cut off, allowing the procedure to be performed without time pressure. The laser fibre used allows simultaneous cutting and coagulation, which contributes to efficient partial kidney resection and may allow better preservation of overall kidney function.
Also performed via cystoscopy is TULA laser therapy (Trans-Urethral Laser Ablation) for non-muscle invasive bladder tumours. One of the advantages of this new technique is the hemostasis provided by the laser. It provides better visibility and optimized hemostasis during the procedure. Compared to the conventional method, it does not require partial or general anaesthesia and can even be performed completely without anaesthesia on an outpatient basis. People who need to take anticoagulants and platelet aggregation inhibitors can also be treated. Thus, the procedure is also suitable for high-risk patients for whom regular ablation is not possible. Since the recurrence rate for bladder tumours is very high, transurethral laser ablation is particularly suitable for multiple applications.